Glancy Prongay & Murray LLP Commences Investigation on Behalf of Halozyme Therapeutics, Inc. Investors (HALO)
Halozyme Therapeutics, Inc. (HALO)
Last halozyme therapeutics, inc. earnings: 2/24 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
halozyme.com/investors/default.aspx
Company Research
Source: Business Wire
LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Halozyme Therapeutics, Inc. (“Halozyme” or the “Company”) (NASDAQ: HALO) investors concerning the Company and its officers’ possible violations of federal securities laws. To obtain information or aid in the investigation, please visit the Halozyme investigation page on our website at www.glancylaw.com/case/halozyme-therapeutics-inc. On January 16, 2018, an abstract was published detailing a study of Halozyme’s drug PEGPH20 as a treatment for pancreatic cancer in combination with the cancer drug mFFOX. The abstract’s authors concluded that the addition of PEGPH20 to mFFOX appears to be detrimental, noting that patients who used the combination experienced higher levels of diarrhea, fatigue, nausea, and vomiting. On this news, Halozyme’s share price fell $1.76, or nearly 9%, to close at $17.98 o
Show less
Read more
Impact Snapshot
Event Time:
HALO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HALO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HALO alerts
High impacting Halozyme Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
HALO
News
- Halozyme Therapeutics (HALO) Upgraded to Buy: Here's What You Should Know [Yahoo! Finance]Yahoo! Finance
- Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $50.00 price target on the stock.MarketBeat
- argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease [Yahoo! Finance]Yahoo! Finance
- Halozyme's Strategic Partnerships Fueling Next-Gen Therapeutics [Seeking Alpha]Seeking Alpha
- Is Now The Time To Put Halozyme Therapeutics (NASDAQ:HALO) On Your Watchlist? [Yahoo! Finance]Yahoo! Finance
HALO
Earnings
- 2/20/24 - Beat
HALO
Sec Filings
- 4/17/24 - Form 4
- 4/17/24 - Form 144
- 4/16/24 - Form 144
- HALO's page on the SEC website